Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis

Pooled results from two identical trials comparing etoricoxib, celecoxib and placebo

Clifton Bingham, Steven S. Smugar, Hongwei Wang, Andrew M. Tershakovec

Research output: Contribution to journalArticle

Abstract

Objective: We evaluated whether early response to NSAIDs predicted later response, and when this was established. Methods: We evaluated pooled data from two identical 26-week, double-blind, randomized trials comparing once-daily etoricoxib 30mg (n = 475), celecoxib 200mg (n = 488) and placebo (n = 244) in patients with knee or hip OA. The present analysis was limited to the 12-week placebo-controlled period. Patient-level OMERACT-OARSI response was determined at 2, 4, 8 and 12 weeks. The proportion of patients who maintained response status between these times was determined from binomial distribution using the exact method. Results: After 12 weeks of treatment, there were significantly more responders in the etoricoxib (59.8%) and celecoxib (57%) groups compared with placebo (34%; P

Original languageEnglish (US)
Pages (from-to)1122-1127
Number of pages6
JournalRheumatology
Volume48
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

etoricoxib
Celecoxib
Cyclooxygenase 2 Inhibitors
Osteoarthritis
Placebos
Binomial Distribution
Non-Steroidal Anti-Inflammatory Agents
Hip
Knee

Keywords

  • Celecoxib
  • Etoricoxib
  • NSAID
  • OMERACT-OARSI
  • Osteoarthritis
  • Responder criteria
  • Response

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis : Pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. / Bingham, Clifton; Smugar, Steven S.; Wang, Hongwei; Tershakovec, Andrew M.

In: Rheumatology, Vol. 48, No. 9, 09.2009, p. 1122-1127.

Research output: Contribution to journalArticle

@article{8b5ad20b6d2b4c6da767f1875c540bff,
title = "Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: Pooled results from two identical trials comparing etoricoxib, celecoxib and placebo",
abstract = "Objective: We evaluated whether early response to NSAIDs predicted later response, and when this was established. Methods: We evaluated pooled data from two identical 26-week, double-blind, randomized trials comparing once-daily etoricoxib 30mg (n = 475), celecoxib 200mg (n = 488) and placebo (n = 244) in patients with knee or hip OA. The present analysis was limited to the 12-week placebo-controlled period. Patient-level OMERACT-OARSI response was determined at 2, 4, 8 and 12 weeks. The proportion of patients who maintained response status between these times was determined from binomial distribution using the exact method. Results: After 12 weeks of treatment, there were significantly more responders in the etoricoxib (59.8{\%}) and celecoxib (57{\%}) groups compared with placebo (34{\%}; P",
keywords = "Celecoxib, Etoricoxib, NSAID, OMERACT-OARSI, Osteoarthritis, Responder criteria, Response",
author = "Clifton Bingham and Smugar, {Steven S.} and Hongwei Wang and Tershakovec, {Andrew M.}",
year = "2009",
month = "9",
doi = "10.1093/rheumatology/kep184",
language = "English (US)",
volume = "48",
pages = "1122--1127",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis

T2 - Pooled results from two identical trials comparing etoricoxib, celecoxib and placebo

AU - Bingham, Clifton

AU - Smugar, Steven S.

AU - Wang, Hongwei

AU - Tershakovec, Andrew M.

PY - 2009/9

Y1 - 2009/9

N2 - Objective: We evaluated whether early response to NSAIDs predicted later response, and when this was established. Methods: We evaluated pooled data from two identical 26-week, double-blind, randomized trials comparing once-daily etoricoxib 30mg (n = 475), celecoxib 200mg (n = 488) and placebo (n = 244) in patients with knee or hip OA. The present analysis was limited to the 12-week placebo-controlled period. Patient-level OMERACT-OARSI response was determined at 2, 4, 8 and 12 weeks. The proportion of patients who maintained response status between these times was determined from binomial distribution using the exact method. Results: After 12 weeks of treatment, there were significantly more responders in the etoricoxib (59.8%) and celecoxib (57%) groups compared with placebo (34%; P

AB - Objective: We evaluated whether early response to NSAIDs predicted later response, and when this was established. Methods: We evaluated pooled data from two identical 26-week, double-blind, randomized trials comparing once-daily etoricoxib 30mg (n = 475), celecoxib 200mg (n = 488) and placebo (n = 244) in patients with knee or hip OA. The present analysis was limited to the 12-week placebo-controlled period. Patient-level OMERACT-OARSI response was determined at 2, 4, 8 and 12 weeks. The proportion of patients who maintained response status between these times was determined from binomial distribution using the exact method. Results: After 12 weeks of treatment, there were significantly more responders in the etoricoxib (59.8%) and celecoxib (57%) groups compared with placebo (34%; P

KW - Celecoxib

KW - Etoricoxib

KW - NSAID

KW - OMERACT-OARSI

KW - Osteoarthritis

KW - Responder criteria

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=70349782995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349782995&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kep184

DO - 10.1093/rheumatology/kep184

M3 - Article

VL - 48

SP - 1122

EP - 1127

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 9

ER -